Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925375 · ClinicalTrials.gov registry record · Phase 2
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
A Phase 2 study of Interstitial Lung Disease and Common Variable Immunodeficiency, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 6
- Study locations
NCT04925375: Recruiting Phase 2 study of Interstitial Lung Disease and Common Variable Immunodeficiency, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT04925375 is a Phase 2 study of Interstitial Lung Disease and Common Variable Immunodeficiency that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 38 participants, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04925375, a Phase 2 study of Interstitial Lung Disease and Common Variable Immunodeficiency, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 6
- Study locations
Study Summary
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD
Primary Outcome
Proportion of subjects achieving a significant response (defined as \>30 percent change in lung tissue disease burden by GLILD) on HRCT after 6 months of abatacept therapy.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Abatacept
Study Locations (6)
California
- University of California, San Francisco - San Francisco
Florida
- University of South Florida - Tampa
Massachusetts
- Lahey Hospital and Medical Center - Burlington
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Duke University Health System - Durham
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What NCT04925375 shows while recruiting
NCT04925375 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Interstitial Lung Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04925375 lists 6 locations in 6 states (California, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04925375 about?
NCT04925375 is a clinical study titled "Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease". There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomize...
What is the current status of trial NCT04925375?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2021-07-14. Estimated completion is 2026-07.
What conditions does trial NCT04925375 study?
This clinical trial studies the following conditions: Interstitial Lung Disease, Common Variable Immunodeficiency.
What interventions are being tested in trial NCT04925375?
The interventions under investigation include: Placebo (OTHER), Abatacept (DRUG).
Who is sponsoring clinical trial NCT04925375?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04925375 being conducted?
This trial has 6 study locations across California, Florida, Massachusetts, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04925375's enrollment target sits among peer trials
38 25th of 36 higher than 12 of 36 other Interstitial Lung Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Interstitial Lung Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
-
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI